Trial Profile
Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glimepiride (Primary) ; Saxagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SPECIFY
- 05 Oct 2018 Primary endpoint has been met. (Proportion of subjects achieving glycemic response defined as Glycosylated hemoglobin (HbA1c) 7.0%) as per results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 29 Mar 2018 Status changed from active, no longer recruiting to completed.